fluorenes

Summary

Summary: A family of diphenylenemethane derivatives.

Top Publications

  1. pmc Malaria case-management following change of policy to universal parasitological diagnosis and targeted artemisinin-based combination therapy in Kenya
    Andrew Nyandigisi
    Division of Malaria Control, Ministry of Public Health and Sanitation, Nairobi, Kenya
    PLoS ONE 6:e24781. 2011
  2. pmc Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania
    Oliver J Sabot
    Malaria Control Team, Clinton Foundation HIV AIDS Initiative, Boston, Massachusetts, USA
    PLoS ONE 4:e6857. 2009
  3. ncbi In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem)
    Christin Sisowath
    Malaria Research Laboratory, Unit of Infectious Diseases, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden
    J Infect Dis 191:1014-7. 2005
  4. pmc Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia
    Pharath Lim
    Institut Pasteur in Cambodia, Phnom Penh, Cambodia
    Malar J 8:11. 2009
  5. pmc Changes in health workers' malaria diagnosis and treatment practices in Kenya
    Elizabeth Juma
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, PO Box 43640, 00100 GPO, Nairobi, Kenya
    Malar J 10:1. 2011
  6. pmc Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial
    Jean Louis A Ndiaye
    Department of Medical Parasitology, Medical Faculty, Universite Cheikh Anta Diop, Dakar, Senegal
    Malar J 10:237. 2011
  7. pmc The impact of retail-sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized controlled trial
    Beth P Kangwana
    Malaria Public Health and Epidemiology Group, Kenya Medical Research Institute Wellcome Trust Research Programme, Kenya
    PLoS Med 8:e1000437. 2011
  8. pmc Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria
    Joel Tarning
    Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Antimicrob Agents Chemother 53:3837-46. 2009
  9. pmc Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia
    Karen I Barnes
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town Faculty of Health Sciences, Anzio Road, Observatory, 7925, South Africa
    Malar J 8:S8. 2009
  10. pmc In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1
    Leah Mwai
    Kenya Medical Research Institute KEMRI Wellcome Trust Collaborative Research Program, Kilifi, Kenya
    Antimicrob Agents Chemother 53:5069-73. 2009

Research Grants

  1. Training in Endocrinology, Diabetes, Clinical Nutrition
    Robert Klein; Fiscal Year: 2007
  2. Alkynyliodonium Salts and Derived Diyls in Synthesis
    Ken Feldman; Fiscal Year: 2009
  3. New Methodology for Indole Alkaloid Syntheses
    Ken Feldman; Fiscal Year: 2007
  4. ELLAGITANNIN AND RELATED CHEMISTRY
    Ken Feldman; Fiscal Year: 2001
  5. RADICAL MEDIATED CYCLIZATION REACTIONS
    Ken Feldman; Fiscal Year: 1993
  6. New Methodology for Indole Alkaloid Syntheses
    Ken S Feldman; Fiscal Year: 2010
  7. Chemical and Biological Studies on Biaryl Phenolics
    Ken Feldman; Fiscal Year: 2005
  8. Burden of Malaria in Pregnancy in India
    Davidson Hamer; Fiscal Year: 2007
  9. ALKYNYLIODONIUM CHEMISTRY IN ORGANIC SYNTHESIS
    Ken Feldman; Fiscal Year: 1999
  10. ALKYNYLIODONIUM SALTS IN ORGANIC SYNTHESIS
    Ken Feldman; Fiscal Year: 2004

Detail Information

Publications260 found, 100 shown here

  1. pmc Malaria case-management following change of policy to universal parasitological diagnosis and targeted artemisinin-based combination therapy in Kenya
    Andrew Nyandigisi
    Division of Malaria Control, Ministry of Public Health and Sanitation, Nairobi, Kenya
    PLoS ONE 6:e24781. 2011
    ..We evaluated changes in health systems and case-management indicators between the baseline survey undertaken before implementation of the policy and the follow-up survey following the first year of the implementation activities...
  2. pmc Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania
    Oliver J Sabot
    Malaria Control Team, Clinton Foundation HIV AIDS Initiative, Boston, Massachusetts, USA
    PLoS ONE 4:e6857. 2009
    ..To overcome this challenge, a global ACT subsidy has been proposed. We tested this proposal through a pilot program in rural Tanzania...
  3. ncbi In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem)
    Christin Sisowath
    Malaria Research Laboratory, Unit of Infectious Diseases, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden
    J Infect Dis 191:1014-7. 2005
    ..This points to 86N as a potential marker of lumefantrine resistance in vivo, while suggesting that Coartem is not robust enough to avoid selection of resistance-associated mutations in some malarial settings...
  4. pmc Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia
    Pharath Lim
    Institut Pasteur in Cambodia, Phnom Penh, Cambodia
    Malar J 8:11. 2009
    ....
  5. pmc Changes in health workers' malaria diagnosis and treatment practices in Kenya
    Elizabeth Juma
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, PO Box 43640, 00100 GPO, Nairobi, Kenya
    Malar J 10:1. 2011
    ..Three years after the policy implementation, health workers' adherence to malaria diagnosis and treatment recommendations was evaluated...
  6. pmc Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial
    Jean Louis A Ndiaye
    Department of Medical Parasitology, Medical Faculty, Universite Cheikh Anta Diop, Dakar, Senegal
    Malar J 10:237. 2011
    ....
  7. pmc The impact of retail-sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized controlled trial
    Beth P Kangwana
    Malaria Public Health and Epidemiology Group, Kenya Medical Research Institute Wellcome Trust Research Programme, Kenya
    PLoS Med 8:e1000437. 2011
    ..This study in western Kenya aimed to evaluate the impact of providing subsidized artemether-lumefantrine (AL) through retail providers on the coverage of prompt, effective antimalarial treatment for febrile children aged 3-59 months...
  8. pmc Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria
    Joel Tarning
    Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Antimicrob Agents Chemother 53:3837-46. 2009
    ..In conclusion, altered pharmacokinetic properties of lumefantrine contribute to the high rates of failure of artemether-lumefantrine treatment in later pregnancy. Dose optimization is urgently needed...
  9. pmc Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia
    Karen I Barnes
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town Faculty of Health Sciences, Anzio Road, Observatory, 7925, South Africa
    Malar J 8:S8. 2009
    ..Artemisinin-based combination therapy has made a substantial contribution to reducing the burden of malaria in sub-Saharan Africa...
  10. pmc In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1
    Leah Mwai
    Kenya Medical Research Institute KEMRI Wellcome Trust Collaborative Research Program, Kilifi, Kenya
    Antimicrob Agents Chemother 53:5069-73. 2009
    ..Therefore, the use of LM-artemether is likely to lead to the selection of more CQ-susceptible parasites...
  11. pmc Quality of malaria case management at outpatient health facilities in Angola
    Alexander K Rowe
    Centers for Disease Control and Prevention, Atlanta, USA
    Malar J 8:275. 2009
    ..Implementation was complicated by a policy that was sometimes ambiguous...
  12. doi Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial
    Antoinette K Tshefu
    Ecole de Santé Publique, Faculte de Medecine, Universite de Kinshasa, Kinshasa, Democratic Republic of the Congo
    Lancet 375:1457-67. 2010
    ..We compared the efficacy and safety of pyronaridine-artesunate with that of artemether-lumefantrine for treatment of uncomplicated P falciparum malaria...
  13. pmc SMS for Life: a pilot project to improve anti-malarial drug supply management in rural Tanzania using standard technology
    Jim Barrington
    SMS for Life Program Director, Forum 1 P 94, Novartis Campus, CH 4056 Basel, Switzerland
    Malar J 9:298. 2010
    ..Lack of visibility of anti-malarial stock levels at the health facility level is an important contributor to this problem...
  14. doi Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial
    Patrice Piola
    Epicentre, Paris, France
    Lancet Infect Dis 10:762-9. 2010
    ..We aimed to assess whether artemether-lumefantrine was at least as efficacious as oral quinine for the treatment of uncomplicated falciparum malaria during the second and third trimesters of pregnancy in Mbarara, Uganda...
  15. pmc In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa
    Christin Sisowath
    Infectious Diseases Unit, Department of Medicine and Karolinska Institutet, Stockholm, Sweden
    J Infect Dis 199:750-7. 2009
    ..Identification of drug-specific parasite determinants that contribute to treatment failures will provide important tools for the detection and surveillance of AL resistance...
  16. pmc Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast
    Steffen Borrmann
    Kenya Medical Research Institute Wellcome Trust Research Programme, Kilifi, Kenya
    PLoS ONE 6:e26005. 2011
    ..The emergence of artemisinin-resistant P. falciparum malaria in South-East Asia highlights the need for continued global surveillance of the efficacy of artemisinin-based combination therapies...
  17. pmc Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial
    Quique Bassat
    Barcelona Centre for International Health Research CRESIB, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
    PLoS ONE 4:e7871. 2009
    ..Dihydroartemisinin-piperaquine (DHA-PQP) is a promising fixed-dose ACT with limited information on its safety and efficacy in African children...
  18. doi A trial of combination antimalarial therapies in children from Papua New Guinea
    Harin A Karunajeewa
    School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia
    N Engl J Med 359:2545-57. 2008
    ..Malaria control is difficult where there is intense year-round transmission of multiple plasmodium species, such as in Papua New Guinea...
  19. ncbi The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa
    Christin Sisowath
    Malaria Research Unit, Division of Infectious Diseases, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Trop Med Int Health 12:736-42. 2007
    ..e. pfmdr1 gene amplification, pfmdr1 Y184F, S1034C, N1042D, D1246Y, pfcrt S163R and PfATP6 S769N...
  20. doi Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial
    Billy E Ngasala
    Malaria Research, Infectious Diseases Unit, Department of Medicine Solna, Karolinska University Hospital, Stockholm, Sweden
    Clin Infect Dis 52:873-82. 2011
    ....
  21. pmc Improved diagnostic testing and malaria treatment practices in Zambia
    Davidson H Hamer
    Center for International Health and Development, Boston University School of Public Health, Boston, Mass 02118, USA
    JAMA 297:2227-31. 2007
    ....
  22. pmc Malaria drug shortages in Kenya: a major failure to provide access to effective treatment
    Beth B Kangwana
    Malaria Public Health and Epidemiology Group, Kenya Medical Research Institute Wellcome Trust Programme Nairobi, Kenya
    Am J Trop Med Hyg 80:737-8. 2009
    ..The shortage was in large part caused by a delayed procurement process. National ministries of health and the international community must address the current shortcomings facing antimalarial drug supply to the public sector...
  23. pmc A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya
    Petra F Mens
    Koninklijk Instituut voor de Tropen KIT Royal Tropical Institute, KIT Biomedical Research, Amsterdam, The Netherlands
    Malar J 7:237. 2008
    ....
  24. pmc In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Central Ethiopia
    Jimee Hwang
    U S Centers for Disease Control and Prevention, Atlanta, GA, USA
    Malar J 10:209. 2011
    ..In Ethiopia, artemether-lumefantrine (AL) has been the first-line treatment for uncomplicated P. falciparum malaria since 2004...
  25. ncbi Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria
    M A van Agtmael
    Department of Clinical Pharmacology and Pharmacotherapy, Academic Medical Center, Amsterdam, The Netherlands
    Int J Antimicrob Agents 12:151-8. 1999
    ..We suggest that auto-induction of gut mucosa enzymes and/or liver enzymes causes a time-dependent increase in first-pass metabolisation of artemether...
  26. doi Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children
    Emmanuel Arinaitwe
    Makerere University University of California San Francisco Research Collaboration, University of California, San Francisco 94143, USA
    Clin Infect Dis 49:1629-37. 2009
    ..However, which therapies are optimal is a matter of debate. We aimed to compare the short- and longer-term efficacy of 2 leading therapies in a cohort of young Ugandan children...
  27. pmc Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania
    Abdunoor M Kabanywanyi
    Ifakara Health Institute, P, O, Box 78373, Kiko Avenue, Old Bagamoyo Road, Mikocheni, Dar es Salaam, Tanzania
    Malar J 9:48. 2010
    ..Controlled clinical trials have shown that a six-dose regimen of artemether-lumefantrine (AL) therapy for uncomplicated Plasmodium falciparum malaria results in cure rates >95% with good tolerability...
  28. pmc Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria?
    Bernhards Ogutu
    Walter Reed Project Centre for Clinical Research Kenya Medical Research Institute, Nairobi, Kenya
    Malar J 9:30. 2010
    ..The potential of this intervention was considered by key scientists in the field at an Advisory Board meeting held in Basel, in April 2009. This article summarizes the discussions that took place among the participants...
  29. pmc Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria
    Anja M Carlsson
    Infectious Diseases Unit, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Retzius väg 10, S 171 77 Stockholm, Sweden
    Malar J 10:380. 2011
    ..This study aimed to explore Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment with artemisinin-based combination therapy in children with clinical malaria in a high transmission area in Africa...
  30. pmc Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania
    Erasmus Kamugisha
    Weill Bugando University College of Health Sciences, Mwanza, Tanzania
    Malar J 11:58. 2012
    ....
  31. pmc Adherence to a six-dose regimen of artemether-lumefantrine among uncomplicated Plasmodium falciparum patients in the Tigray Region, Ethiopia
    Hailemariam Lemma
    Tigray Health Bureau, Mekelle, Ethiopia
    Malar J 10:349. 2011
    ..The aim of this study was to measure patient adherence levels to the six-dose AL regimen for the treatment of uncomplicated P. falciparum malaria and to identify its determinant factors in rural areas of the Tigray region, Ethiopia..
  32. ncbi Probing the conformational heterogeneity of the acetylaminofluorene-modified 2'-deoxyguanosine and DNA by 19F NMR spectroscopy
    B P Cho
    Department of Biomedical Sciences, College of Pharmacy, University of Rhode Island, Kingston 02881, USA
    Biochemistry 38:7572-83. 1999
    ..et al. (1997) J. Am. Chem. Soc. 119, 5384-5389]. The exclusive stacked nature of the AAF adducts may provide insight into why AAF adducts are more mutagenic and prone to repair than the nonacetylated AF adducts...
  33. pmc Influence of flanking sequence context on the conformational flexibility of aminofluorene-modified dG adduct in dA mismatch DNA duplexes
    Nidhi Jain
    Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA
    Nucleic Acids Res 37:1628-37. 2009
    ....
  34. pmc Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine
    Shabana Ali
    Department of Pharmacology and Therapeutics, Army Medical College, National University of Sciences and Technology NUST, Islamabad, Pakistan
    Malar J 9:275. 2010
    ..The aim of this study was to evaluate the pharmacokinetics of artemether and its active metabolite, dihydroartemisinin, in healthy Pakistani volunteers...
  35. pmc The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria
    Quique Bassat
    Barcelona Centre for International Health Research CRESIB, Hospital Clínic Universitat de Barcelona, Barcelona, Spain
    PLoS Negl Trop Dis 5:e1325. 2011
    ..vivax, and in co-endemic areas where AL is already used routinely against P. falciparum and parasitological differentiation is not routinely performed or only clinical diagnosis is used...
  36. pmc Implementation of Home based management of malaria in children reduces the work load for peripheral health facilities in a rural district of Burkina Faso
    Alfred B Tiono
    Centre National de Recherche et de Formation sur Paludisme, Ministère de Santé, Ouagadougou, Burkina Faso, West Africa
    Malar J 7:201. 2008
    ..However, the potential fall-out of this community-based strategy on the work burden at the peripheral health facilities level has never been investigated...
  37. pmc Adherence to prescribed artemisinin-based combination therapy in Garissa and Bunyala districts, Kenya
    Harriet Lawford
    The MENTOR Initiative, La Prade, 11150, Villasavary, France
    Malar J 10:281. 2011
    ..This study reports adherence to a specific ACT, artemether-lumefantrine (AL), under conditions of routine clinical practice in Kenya...
  38. pmc Accessibility, availability and affordability of anti-malarials in a rural district in Kenya after implementation of a national subsidy scheme
    Nathan Smith
    Duke Global Health Institute, Trent Hall, Durham, North Carolina, USA
    Malar J 10:316. 2011
    ..The goal of this strategy is to make ACT as affordable as ineffective alternatives. The programme, called the Affordable Medicines Facility - malaria was rolled out in Kenya in August 2010...
  39. pmc Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study
    Billy E Ngasala
    Malaria Research, Infectious Diseases Unit, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Malar J 10:64. 2011
    ....
  40. pmc Malaria case-management under artemether-lumefantrine treatment policy in Uganda
    Dejan Zurovac
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, Nairobi, Kenya
    Malar J 7:181. 2008
    ..Here the quality of AL case-management is reported from Uganda; approximately one year after AL replaced combination of chloroquine and sulphadoxine-pyrimethamine (CQ+SP) as recommended first line treatment for uncomplicated malaria...
  41. pmc Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania
    Sofia Friberg Hietala
    Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden
    Antimicrob Agents Chemother 54:4780-8. 2010
    ..However, the poor precision in some parameters illustrates the need for further data to support and refine this model...
  42. pmc Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin
    Amar bir Singh Sidhu
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, Bronx, NY 10461, USA
    J Infect Dis 194:528-35. 2006
    ..These results highlight the importance of pfmdr1 copy number in determining P. falciparum susceptibility to multiple agents currently being used to combat malaria caused by multidrug-resistant parasites...
  43. pmc Site-specific incorporation of N-(deoxyguanosin-8-yl)-2-acetylaminofluorene (dG-AAF) into oligonucleotides using modified 'ultra-mild' DNA synthesis
    Ludovic C J Gillet
    Institute for Molecular Cancer Research, University of Zürich August Forel Strasse 7, 8008 Zurich, Switzerland
    Nucleic Acids Res 33:1961-9. 2005
    ..Our synthetic approach should facilitate comprehensive studies of the mechanisms of repair and mutagenesis induced by dG-AAF adducts in DNA and should be of general use for the incorporation of base-labile functionalities into DNA...
  44. doi Increased prevalence of the Plasmodium falciparum Pfmdr1 86N genotype among field isolates from Franceville, Gabon after replacement of chloroquine by artemether-lumefantrine and artesunate-mefloquine
    Jean Bernard Lekana-Douki
    Unité de Parasitologie Médicale UPARAM, Centre International de Recherches Medicales de Franceville CIRMF, B P 769 Franceville, Gabon
    Infect Genet Evol 11:512-7. 2011
    ....
  45. pmc Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria
    C T Happi
    Malaria Research Laboratories, IMRAT, College of Medicine, University of Ibadan, Ibadan, Nigeria
    Antimicrob Agents Chemother 53:888-95. 2009
    ..Pfmdr1 polymorphisms may result in reduction in the therapeutic efficacy of this newly adopted combination treatment for uncomplicated falciparum malaria in Saharan countries of Africa...
  46. pmc Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi
    David J Bell
    Tropical and Infectious Diseases Unit, Royal Liverpool University Hospital, Liverpool L7 8XP, UK
    Malar J 8:204. 2009
    ..The aim of this study was to investigate the impact of poor adherence on the effectiveness of AL and CPD...
  47. pmc Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria
    Zul Premji
    Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
    PLoS ONE 4:e6682. 2009
    ....
  48. ncbi Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria
    Ric N Price
    Centre for Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom
    Clin Infect Dis 42:1570-7. 2006
    ..Our study examined the relative contributions of host, pharmacokinetic, and parasitological factors in determining the therapeutic response to artemether-lumefantrine (AL)...
  49. ncbi Effect of malaria rapid diagnostic tests on the management of uncomplicated malaria with artemether-lumefantrine in Kenya: a cluster randomized trial
    Jacek Skarbinski
    Malaria Branch, US Centers for Disease Control and Prevention, Atlanta, Georgia 30341 3724, USA
    Am J Trop Med Hyg 80:919-26. 2009
    ..30). RDTs could potentially improve malaria case management, but we urgently need to develop more effective strategies for implementing guidelines before large scale implementation...
  50. pmc Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia
    Christine Manyando
    Tropical Diseases Research Centre, Ndola, Zambia
    Malar J 9:249. 2010
    ..Safety data regarding exposure to artemisinin-based combination therapy in pregnancy are limited. This prospective cohort study conducted in Zambia evaluated the safety of artemether-lumefantrine (AL) in pregnant women with malaria...
  51. pmc Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria
    Sam Salman
    School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia
    Antimicrob Agents Chemother 55:5306-13. 2011
    ....
  52. pmc Early variations in plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance
    Obaro S Michael
    Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria
    Malar J 9:335. 2010
    ..The study protocol was designed to evaluate more closely the early effects and the standard measures of efficacies of these two regimens...
  53. doi Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast
    Babacar Faye
    Service de Parasitologie Mycologie Médicale, Universite Cheikh Anta Diop, Dakar Fann, Senegal
    Trop Med Int Health 15:608-13. 2010
    ....
  54. pmc Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms
    Maja Malmberg
    Malaria Research, Infectious Disease Unit, Department of Medicine Solna, Stockholm, Sweden
    J Infect Dis 207:842-7. 2013
    ..The aim of this study was to investigate the extent to which parasites with different genetic characteristics are able to withstand individual drug blood concentrations...
  55. pmc No evidence for spread of Plasmodium falciparum artemisinin resistance to Savannakhet Province, Southern Laos
    Mayfong Mayxay
    Wellcome Trust Mahosot Hospital Oxford University Tropical Medicine Research Collaboration, Mahosot Hospital, Vientiane, Laos
    Am J Trop Med Hyg 86:403-8. 2012
    ..Serious adverse events did not develop during or after treatment in any patients. In conclusion, no evidence of P. falciparum in vivo resistance to artesunate was found in southern Laos...
  56. pmc Rapid selection of Plasmodium falciparum chloroquine resistance transporter gene and multidrug resistance gene-1 haplotypes associated with past chloroquine and present artemether-lumefantrine use in Inhambane District, southern Mozambique
    Thomas T Thomsen
    Section for Functional Genomics, Department of Biology, University of Copenhagen, Ole Maaløes Vej 5, 2200 Copenhagen N, Denmark
    Am J Trop Med Hyg 88:536-41. 2013
    ..In the absence of a clear AL-resistance marker and the (almost) continent-wide use of AL in sub-Saharan Africa, and when considering CQ reintroduction, continued monitoring of these markers is needed...
  57. pmc Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients
    T Kredo
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    Antimicrob Agents Chemother 55:5616-23. 2011
    ..The mechanism of the lumefantrine interaction remains to be elucidated. Studies investigating the interaction of nevirapine and artemether-lumefantrine in HIV-infected patients with malaria are urgently needed...
  58. pmc Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda
    Joel Tarning
    Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
    Malar J 11:293. 2012
    ..The objective of this study was to evaluate the population pharmacokinetic properties of artemether and its active metabolite dihydroartemisinin in pregnant women with uncomplicated P. falciparum malaria in Uganda...
  59. ncbi Mutagenic events in Escherichia coli and mammalian cells generated in response to acetylaminofluorene-derived DNA adducts positioned in the Nar I restriction enzyme site
    Xingzhi Tan
    Laboratory of Chemical Biology, Department of Pharmacological Sciences, State University of New York at Stony Brook, Stony Brook, New York 11794 8651, USA
    Biochemistry 41:14255-62. 2002
    ..3-21%, the higher value at G(2). We conclude from this study that the mutation potential of dG-AAF and dG-AF depends on the structure of the adduct, the sequence context of the lesion, and the host cell used for the experiment...
  60. pmc Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda
    Frederick N Baliraine
    Department of Medicine, University of California, San Francisco, CA 94143 0811, USA
    J Infect Dis 204:1120-4. 2011
    ..Thus, parasites selected for decreased drug sensitivity can appear long after predicted exposure to antimalarial drugs. Continued surveillance of the clinical efficacy and in vitro activity of new combination therapies is warranted...
  61. pmc Patterns of anti-malarial drug treatment among pregnant women in Uganda
    Laura R Sangaré
    Department of Global Health, University of Washington, Seattle, WA, USA
    Malar J 10:152. 2011
    ..The study objective was to determine the degree to which presumed episodes of uncomplicated symptomatic malaria in pregnancy were treated with a recommended anti-malarial regimen in a region of Uganda...
  62. pmc Feasibility and acceptability of artemisinin-based combination therapy for the home management of malaria in four African sites
    IkeOluwapo O Ajayi
    Malaria Research Laboratories, Institute of Medical Research and Training, College of Medicine, University of Ibadan, Nigeria
    Malar J 7:6. 2008
    ..The feasibility and acceptability of incorporating ACT in HMM needs to be evaluated...
  63. pmc Conformational and thermodynamic properties modulate the nucleotide excision repair of 2-aminofluorene and 2-acetylaminofluorene dG adducts in the NarI sequence
    Vipin Jain
    Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI 02881, USA
    Nucleic Acids Res 40:3939-51. 2012
    ..The present results provide valuable conformational insight into the sequence-dependent UvrABC incisions of the bulky aminofluorene DNA adducts...
  64. doi Adherence to artemether/lumefantrine treatment in children under real-life situations in rural Tanzania
    Daudi O Simba
    Department of Community Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
    Trans R Soc Trop Med Hyg 106:3-9. 2012
    ....
  65. pmc Association between the pfmdr1 gene and in vitro artemether and lumefantrine sensitivity in Thai isolates of Plasmodium falciparum
    Mathirut Mungthin
    Department of Parasitology, Phramongkutklao College of Medicine, Bangkok, Thailand
    Am J Trop Med Hyg 83:1005-9. 2010
    ..Separate analysis also indicated that parasites from different geographical areas were influenced by different genetic markers...
  66. doi The effects of a pre-season treatment with effective antimalarials on subsequent malaria morbidity in under five-year-old children living in high and seasonal malaria transmission area of Burkina Faso
    Alphonse Ouedraogo
    Centre National de Recherche et de Formation sur le Paludisme, Ministere de la Sante, Ouagadougou, Burkina Faso Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso
    Trop Med Int Health 15:1315-21. 2010
    ..To evaluate the effects of pre-season treatment with single dose of sulfadoxine-pyrimethamine (SP) or artemether-lumefantrine (AL) on subsequent malaria morbidity in under-fives...
  67. pmc Treatment with coartem (artemether-lumefantrine) in Papua New Guinea
    Sonja Schoepflin
    Swiss Tropical Institute, Basel, Switzerland
    Am J Trop Med Hyg 82:529-34. 2010
    ..In contrast to the situation in classic drug trials with ideal treatment conditions, our field survey highlights potential problems with unsupervised usage of Coartem in routine clinical practice and under program conditions...
  68. pmc Community response to artemisinin-based combination therapy for childhood malaria: a case study from Dar es Salaam, Tanzania
    Vinay R Kamat
    Department of Anthropology, University of British Columbia, Vancouver, Canada
    Malar J 9:61. 2010
    ..The paper specifically examines the perceived efficacy of ALu as articulated by the mothers of young children diagnosed with malaria and prescribed ALu...
  69. pmc Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria
    F Ezzet
    Novartis Pharma AG, Basel, Switzerland
    Antimicrob Agents Chemother 44:697-704. 2000
    ..The high cure rates with the two six-dose regimens resulted from increased AUC and increased time at which lumefantrine concentrations were above the in vivo MIC...
  70. pmc Overuse of artemisinin-combination therapy in Mto wa Mbu (river of mosquitoes), an area misinterpreted as high endemic for malaria
    Charles Mwanziva
    Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Malar J 7:232. 2008
    ..This study describes diagnostic and treatment practices in Mto wa Mbu, an area that used to be hyperendemic for malaria, but where no recent assessments of transmission intensity have been conducted...
  71. pmc Probing the sequence effects on NarI-induced -2 frameshift mutagenesis by dynamic 19F NMR, UV, and CD spectroscopy
    Nidhi Jain
    Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island 02881, USA
    Biochemistry 46:13310-21. 2007
    ..We also provide evidence for AF/FAF conformational compatibility in the NarI sequences...
  72. ncbi The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria
    Rose McGready
    Shoklo Malaria Research Unit, P O Box 46, Mae Sot, Tak, Thailand
    Eur J Clin Pharmacol 62:1021-31. 2006
    ..To determine the pharmacokinetic properties of artemether and lumefantrine (AL) in pregnant women with recrudescent uncomplicated multi-drug resistant falciparum malaria...
  73. pmc Health facility and health worker readiness to deliver new national treatment policy for malaria in Kenya
    J Njogu
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, P O Box 43640 00100, Nairobi, Kenya
    East Afr Med J 85:213-21. 2008
    ..To evaluate health facility and health worker readiness to deliver new artemether-lumefantrine (AL) treatment policy for uncomplicated malaria in Kenya...
  74. pmc Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal
    Babacar Faye
    Laboratoire de Parasitologie Mycologie, Faculte de Medecine, Pharmacie et Odontologie, Universite Cheikh Anta Diop, Dakar, Senegal
    Malar J 6:80. 2007
    ....
  75. pmc Why don't health workers prescribe ACT? A qualitative study of factors affecting the prescription of artemether-lumefantrine
    Beatrice Wasunna
    Eastern and Southern Africa Centre of International Parasite Control ESACIPAC KEMRI, P O Box 54840 00200, Nairobi, Kenya
    Malar J 7:29. 2008
    ..New national guidelines on the diagnosis, treatment and prevention were developed and disseminated to health workers together with in-service training...
  76. pmc Translation of artemether-lumefantrine treatment policy into paediatric clinical practice: an early experience from Kenya
    D Zurovac
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, Nairobi, Kenya
    Trop Med Int Health 13:99-107. 2008
    ..To describe the quality of outpatient paediatric malaria case-management approximately 4-6 months after artemether-lumefantrine (AL) replaced sulfadoxine-pyrimethamine (SP) as the nationally recommended first-line therapy in Kenya...
  77. ncbi [Efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Hainan, China]
    Shan Qing Wang
    Hainan Provincial Center for Disease Control and Prevention, Haikou 570203, China
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 26:50-2. 2008
    ....
  78. ncbi Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper
    D Blessborn
    Dalarna University College, Borlange, Sweden
    J Pharm Biomed Anal 45:282-7. 2007
    ..Lumefantrine could be estimated accurately enough to assess bioavailability and treatment compliance on day 7 (i.e. 4 days after the last dose) after a standard regimen with the lumefantrine/artemether combination...
  79. pmc Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects
    Salim Abdulla
    Ifakara Health Institute, Ifakara and Dar es Salaam, Tanzania
    Malar J 9:253. 2010
    ....
  80. doi Effect of an aldose reductase inhibitor on alveolar bone loss associated with periodontitis in diabetic rats
    Peter F Kador
    College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA
    Postgrad Med 122:138-44. 2010
    ..05). These results suggest that the sorbitol pathway plays a critical role in the pathophysiological mechanism(s) of diabetic periodontitis and that AR may be a direct pharmacological target for the treatment for this disease...
  81. doi Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan
    I Adam
    University of Khartoum, Sudan
    Ann Trop Med Parasitol 104:319-26. 2010
    ..Thus, both treatments appeared effective and safe for the treatment of uncomplicated P. falciparum malaria in central Sudan, although treatment with DHA-P (which requires a simpler dosing regimen) might be preferred to treatment with AL...
  82. pmc Crystal structures of 2-acetylaminofluorene and 2-aminofluorene in complex with T7 DNA polymerase reveal mechanisms of mutagenesis
    Shuchismita Dutta
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:16186-91. 2004
    ..In contrast, the dG-AF base at the templating position is not well defined by the electron density, consistent with weak binding to the polymerase and a possible interchange of this adduct between the syn and anti conformations...
  83. ncbi The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France
    M van Agtmael
    Department of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Centre, Amsterdam, The Netherlands
    Int J Antimicrob Agents 12:159-69. 1999
    ..For travellers contracting malaria abroad, we propose a six-dose regimen of CGP 56697 over 3 days...
  84. ncbi Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats
    P F Kador
    Laboratory of Ocular Therapeutics, National Eye Institute, NIH, Bethesda, Maryland 20892 1850, USA
    J Ocul Pharmacol Ther 16:149-60. 2000
    ..These results support the concept that sugar cataract formation is initiated by the aldose reductase catalyzed intracellular accumulation of polyols and that these sugar cataracts can be prevented through inhibition of aldose reductase...
  85. ncbi Comparative study on the in vitro activity of lumefantrine and desbutyl-benflumetol in fresh isolates of Plasmodium vivax from Thailand
    Daniela K Pirker-Krassnig
    Division of Specific Prophylaxis and Tropical Medicine, Center for Physiology and Pathophysiology, Medical University of Vienna, Austria
    Wien Klin Wochenschr 116:47-52. 2004
    ..0. The activity of desbutyl-benflumetol in P. vivax exceeds that of lumefantrine by one order of magnitude, suggesting a high, hitherto unexploited therapeutic potential of desbutyl-benflumetol...
  86. ncbi Coartemether (artemether and lumefantrine): an oral antimalarial drug
    Walther H Wernsdorfer
    Department of Specific Prophylaxis and Tropical Medicine, University of Vienna, Kinderspitalgasse 15, A 1095 Vienna, Austria
    Expert Rev Anti Infect Ther 2:181-96. 2004
    ..Extensive cardiological investigations have demonstrated the high cardiac safety of coartemether...
  87. doi Comparison of HPLC, UV spectrophotometry and potentiometric titration methods for the determination of lumefantrine in pharmaceutical products
    Isabela da Costa César
    Departamento de Produtos Farmacêuticos, Faculdade de Farmacia, Universidade Federal de Minas Gerais, Av Pres Antônio Carlos 6627, 31270 901 Belo Horizonte, MG, Brazil
    J Pharm Biomed Anal 48:223-6. 2008
    ..The end point was potentiometrically determined. The three evaluated methods showed to be adequate to quantify lumefantrine in raw materials, while HPLC and UV methods presented the most reliable results for the analyses of tablets...
  88. pmc Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children
    Shereen Katrak
    Oregon Health and Science University, Portland, USA
    Malar J 8:272. 2009
    ..However, there is limited data on the safety and tolerability of these drugs, especially in young children and patients co-infected with HIV...
  89. doi Simultaneous determination of artemether and lumefantrine in fixed dose combination tablets by HPLC with UV detection
    Isabela da Costa César
    Departamento de Produtos Farmacêuticos, Faculdade de Farmacia, Universidade Federal de Minas Gerais, Av Pres Antônio Carlos 6627, 31270 901 Belo Horizonte, MG, Brazil
    J Pharm Biomed Anal 48:951-4. 2008
    ..Four batches of artemether-lumefantrine tablets were assayed by the validated method. The artemether contents in the tablets varied from 98.61% to 103.35%, while lumefantrine contents were 97.92-100.48%...
  90. pmc Drug procurement, the Global Fund and misguided competition policies
    Richard Tren
    Africa Fighting Malaria, Washington, DC, USA
    Malar J 8:305. 2009
    ..A tender process based primarily on price cannot account for a company's ability to consistently supply sufficient product in time...
  91. ncbi Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda
    Carole Fogg
    Epicentre, Paris, France
    Am J Trop Med Hyg 71:525-30. 2004
    ..The high adherence to artemether-lumefantrine found in our study suggest that this drug is likely to be very effective in Mbarara provided that patients receive clear dosage explanations...
  92. pmc Understanding the pharmacokinetics of Coartem
    Abdoulaye Djimde
    Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Odonto Stomatology, University of Bamako, PO Box 1805 Point G, Bamako, Mali
    Malar J 8:S4. 2009
    ..However, additional data would be warranted to better characterize artemether and lumefantrine pharmacokinetics in patients with hepatic impairment, in pregnant women, and in patients undergoing HIV/AIDS chemotherapy...
  93. ncbi Monitoring the therapeutic efficacy of antimalarials against uncomplicated falciparum malaria in Thailand
    C Rojanawatsirivej
    Malaria Division, Ministry of Public Health, Nonthaburi, Thailand
    Southeast Asian J Trop Med Public Health 34:536-41. 2003
    ....
  94. pmc Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects
    Gilbert Lefèvre
    Clinical Pharmacology, Novartis Pharma Ltd, WSJ 27 3 102, CH 4002 Basel, Switzerland
    Br J Clin Pharmacol 54:485-92. 2002
    ..To evaluate whether the potent CYP3A4 inhibitor ketoconazole has any influence on the pharmacokinetic and electrocardiographic parameters of the antimalarial co-artemether (artemether-lumefantrine) in healthy subjects...
  95. pmc From chloroquine to artemisinin-based combination therapy: the Sudanese experience
    E M Malik
    National Malaria Control Programme, Khartoum, Sudan
    Malar J 5:65. 2006
    ..Relevant published and unpublished documents were reviewed. Data and information obtained were compiled into a structured format...
  96. ncbi Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects
    Gilbert Lefèvre
    Novartis Pharma Ltd, Basle, Switzerland
    J Clin Pharmacol 42:1147-58. 2002
    ....
  97. ncbi [Surveillance of falciparum malaria susceptibility to antimalarial drugs and policy change in the Comoros]
    R Silai
    Programme National de Lutte contre le Paludisme, Moroni, Union des Comores
    Bull Soc Pathol Exot 100:6-9. 2007
    ..4% in the 3 sites with a follow-up of 28 days. No serious drug related adverse event was reported...
  98. pmc Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand
    S Krudsood
    Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Ratchadewee, Bangkok, Thailand
    Southeast Asian J Trop Med Public Health 34:316-21. 2003
    ..No serious adverse events occurred. We concluded that both DNP and Coartem/ Riamet were safe, well tolerated and highly efficacious in the treatment of acute uncomplicated falciparum malaria in Thailand...
  99. ncbi Efficacy and safety of the six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in adolescents and adults: a pooled analysis of individual patient data from randomized clinical trials
    Edgar A Mueller
    Institute for Clinical Pharmacology, Public Health Research Association Saxony, Medical Faculty, Technical University, Fiedlerstrasse 27, D 01307 Dresden, Germany
    Acta Trop 100:41-53. 2006
    ..The main finding of our analysis is that the six-dose regimen of co-artemether is more effective than the four-dose regimen in adolescents and adults without compromising safety...
  100. pmc Cost-effectiveness study of three antimalarial drug combinations in Tanzania
    Virginia Wiseman
    Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom
    PLoS Med 3:e373. 2006
    ..Cost is a major barrier to deployment. There is little evidence from field trials on the cost-effectiveness of these new combinations...
  101. pmc Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children
    Catherine Maiteki-Sebuguzi
    Department of Medicine, Makerere University, Kampala, Uganda
    Malar J 7:106. 2008
    ..This study compared the safety and tolerability of three combination antimalarial regimens in a cohort of Ugandan children...

Research Grants134 found, 100 shown here

  1. Training in Endocrinology, Diabetes, Clinical Nutrition
    Robert Klein; Fiscal Year: 2007
    ..This program seeks to train independent academic endocrinologists who will function as independent laboratory scientists capable of developing research programs that address endocrine disorders in the future. ..
  2. Alkynyliodonium Salts and Derived Diyls in Synthesis
    Ken Feldman; Fiscal Year: 2009
    ..abstract_text> ..
  3. New Methodology for Indole Alkaloid Syntheses
    Ken Feldman; Fiscal Year: 2007
    ..The use of a new variant of the Pummerer reaction to control both oxidation level and reaction site within the indole nucleus forms the basis of this chemistry. ..
  4. ELLAGITANNIN AND RELATED CHEMISTRY
    Ken Feldman; Fiscal Year: 2001
    ..Finally new strategies for diasteroselective biaryl astropisomer assembly within the context of synthesis efforts directed toward the potent cytotoxic agent diazonamide A will extend current art in this area ..
  5. RADICAL MEDIATED CYCLIZATION REACTIONS
    Ken Feldman; Fiscal Year: 1993
    ..Successful completion of these syntheses will afford the targets (or analogs) in the most efficient manner to date...
  6. New Methodology for Indole Alkaloid Syntheses
    Ken S Feldman; Fiscal Year: 2010
    ..The use of a new variant of the Pummerer reaction to control both oxidation level and reaction site within the indole nucleus forms the basis of this chemistry. ..
  7. Chemical and Biological Studies on Biaryl Phenolics
    Ken Feldman; Fiscal Year: 2005
    ..The search for selective 20S proteosome inhibitors among the Ntn-type proteases will be advanced by these investigations. ..
  8. Burden of Malaria in Pregnancy in India
    Davidson Hamer; Fiscal Year: 2007
    ..The information generated by the study will also be instrumental in the development of new programs for preventing and mitigating the impact of MIP in India. ..
  9. ALKYNYLIODONIUM CHEMISTRY IN ORGANIC SYNTHESIS
    Ken Feldman; Fiscal Year: 1999
    ....
  10. ALKYNYLIODONIUM SALTS IN ORGANIC SYNTHESIS
    Ken Feldman; Fiscal Year: 2004
    ..Taken together, these studies will introduce new and concise techniques for preparing small polycyclic organic molecules of the type typically sought as pharmaceutical leads. ..
  11. Carcinogenicity of Estrogens
    DAVID SPINK; Fiscal Year: 2007
    ..These studies may elucidate roles of estrogen in the regulation of Ah responsiveness, CYP1 expression, and carcinogen bioactivation that may lead to novel breast cancer chemoprevention strategies. ..
  12. Carcinogen Exposure and Adult Cancer Risk
    CHARLENE MCQUEEN; Fiscal Year: 2007
    ..Since tumors are characterized by an accumulation of genetic changes, increasing the mutational burden with exposures early in life has the potential to increase adult cancer risk. ..
  13. TOTAL SYNTHESIS OF AZADIRACHTIN
    K Nicolaou; Fiscal Year: 2007
    ..The proposed work is expected to impact the general areas of pharmaceutical and agricultural research, and infectious diseases in particular, through discoveries in synthetic organic chemistry and chemical biology. ..
  14. THE ROLE OF SULFATIDES IN ALZHEIMER'S DISEASE
    Xianlin Han; Fiscal Year: 2007
    ..abstract_text> ..
  15. SYNTHESIS OF ANTIBIOTICS
    K Nicolaou; Fiscal Year: 2007
    ....
  16. Study of a New Class of Chiral Nucleophilic Catalysts
    VLADIMIR BIRMAN; Fiscal Year: 2007
    ....
  17. Roles of CYP1 & 19 in Fundulus Steroids & PAH Metabolism
    Kristine Willett; Fiscal Year: 2009
    ..This research will further define the utility of Fundulus as a model organism for studying PAH-associated toxicities and in the development of human CYP19 or CYP1 B-related therapeutics. ..
  18. Investigating the Molecular Mechanism of Hexose-induced Stress in Lens and Retina
    Peter F Kador; Fiscal Year: 2010
    ..Moreover, these studies should help identify new drug targets for the treatment of these diabetic complications. ..
  19. Sequence Effects of Arylamine-DNA Adducts: Repair and Replication
    Bongsup P Cho; Fiscal Year: 2010
    ..The key molecular players (adduct structures, polymerases, repair proteins) producing adverse outcomes must be identified, characterized, and understood in order to devise appropriate prevention and risk assessment strategies. ..
  20. The Cytoskeletal System in Preservation Injury
    Martin J Mangino; Fiscal Year: 2010
    ..This will reveal novel therapeutic targets to focus treatments and help alleviate the donor shortage. ..
  21. PHYSIOLOGICALLY ACTIVE NATURAL PRODUCTS
    Douglass Taber; Fiscal Year: 2003
    ..Specific targets include the cognition-enhancing alkaloid huperzine A, morphine, the parent compound of the morphine alkaloids, and N-deacetyllappaconitine, representative of the Delphinium diterpenoid alkaloids. ..
  22. Prevention of Breast Cancer-Targeting COX-2 & PPARgamma
    ALAA BADAWI; Fiscal Year: 2003
    ..abstract_text> ..
  23. Small molecule inhibitors of bacterial secretion system
    Vincent Lee; Fiscal Year: 2007
    ..Furthermore, the small molecule inhibitors identified in this proposal may be used as a starting point for the development of therapeutics to inhibit bacterial infection caused by Gram-negative pathogens that utilize type III secretion. ..
  24. Effective Countermeasures to Anthrax and Botulinum Toxin
    Yuan Ping Pang; Fiscal Year: 2003
    ..It complements the efforts of other workers in developing methods for rapidly identifying anthrax and botulinum toxin. ..
  25. TOTAL SYNTHESIS OF THIOSTREPTON
    K Nicolaou; Fiscal Year: 2005
    ..The disease areas likely to benefit most from the proposed investigations are bacterial-caused diseases and malaria. ..